NCT06624046

Brief Summary

People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population. Improving sleep regularity has been associated with improved glycemic markers however mechanisms by which improving sleep regularity improves metabolic and cardiovascular health is not known. The investigators propose to conduct a mechanistic study using a sleep stability manipulation. This proposal will advance the understanding of mechanisms by which improving sleep regularity influences glycemic control and cardiovascular risk in T1D.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
39mo left

Started Mar 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress27%
Mar 2025Aug 2029

First Submitted

Initial submission to the registry

September 27, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 2, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

March 13, 2025

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2029

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2029

Last Updated

August 11, 2025

Status Verified

August 1, 2025

Enrollment Period

4 years

First QC Date

September 27, 2024

Last Update Submit

August 5, 2025

Conditions

Keywords

sleepcardiovascular disease riskglycemic control

Outcome Measures

Primary Outcomes (3)

  • Glycemic status

    Continuous glucose monitor (CGM)

    From enrollment to week 12

  • Glycemic control

    Hemoglobin A1C

    From enrollment to week 12

  • Insulin sensitivity

    Insulin sensitivity

    From enrollment to week 12

Secondary Outcomes (11)

  • Circadian regulation DLMO

    enrollment to week 12

  • Circadian regulation Melatonin

    Enrollment to week 12

  • Circadian regulation actigraphy

    enrollment to week 12

  • Circadian regulation CLOCK gene

    enrollment to week 12

  • Circadian regulation light

    enrollment to week 12

  • +6 more secondary outcomes

Study Arms (1)

Single arm

OTHER

Sleep stability intervention

Behavioral: Sleep stability intervention

Interventions

The sleep stability intervention will consist of three theory-based intervention components our team has developed and used in prior interventions: 1) self-monitoring using a wearable sleep tracker (Fitbit). This is well-liked by participants and increases awareness of their sleep goals. 2) Accountability coaching via weekly check-ins and daily monitoring of participants' wearable sleep tracking data and a coaching protocol.

Single arm

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Adults 18-50 years with a clinical diagnosis of T1D for at least one year
  • Report habitual sleep irregularity ≥1 hour/week
  • Desire to improve sleep, and own a smartphone (Android or iPhone)

You may not qualify if:

  • Self-reported A1C within the past 6 months ≥10%
  • insomnia symptoms defined as Insomnia Severity Index score ≥15
  • history of restless leg syndrome
  • history of severe hypoglycemia (defined as hypoglycemic episode that results in loss of consciousness, seizure, or requiring emergency room visit or hospitalization) within the past 6 months
  • rotating shift or night work or routinely sleeping after 3 AM.
  • use of sleep medications/aids, significant medical comorbidities (such as heart failure, cirrhosis, chronic obstructive pulmonary disease requiring oxygen, active treatment for cancer, on renal replacement therapy \[dialysis\])
  • depression (Patient Health Questionnaire 8 \[PHQ-8\] score ≥15)
  • history of stroke with neurological deficits
  • pregnant, breast feeding, or planning pregnancy, as sleep and glucose are known to change during pregnancy and breastfeeding.
  • Allergy to lidocaine Participants who passed the first screen by phone will be scheduled for a consenting visit at UIC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Illinois Chicago

Chicago, Illinois, 60612, United States

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Pamela Martyn-Nemeth, PhD

CONTACT

Sirimon Reutrakul, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Model Details: Single arm, pretest, post-test design using a sleep stability intervention
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 27, 2024

First Posted

October 2, 2024

Study Start

March 13, 2025

Primary Completion (Estimated)

February 28, 2029

Study Completion (Estimated)

August 31, 2029

Last Updated

August 11, 2025

Record last verified: 2025-08

Locations